1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: USPHS/IDSA prevention of opportunistic infections working group

Clinical Infectious Diseases

Volumn 30, Issue 4 SUPPL. 1, 2000, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIINFECTIVE AGENT; ATOVAQUONE; AZITHROMYCIN; CIDOFOVIR; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPSONE; ETHAMBUTOL; FAMCICLOVIR; FLUCONAZOLE; FOLINIC ACID; FOSCARNET; GANCICLOVIR; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HERPES ZOSTER IMMUNOGLOBULIN; ISONIAZID; ITRACONAZOLE; PENTAMIDINE; PNEUMOCOCCUS VACCINE; PYRAZINAMIDE; PYRIDOXINE; RIFABUTIN; RIFAMPICIN; SULFADIAZINE; UNINDEXED DRUG;

CYTOMEGALOVIRUS INFECTION; DRUG COST; FOOD DRUG INTERACTION; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; MYCOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; TUBERCULOSIS;

EID: 0033798496     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313848     Document Type: Review

References (95)

1. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: A summary
2. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations
3. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: A summary
4. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
5. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations
6. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
7. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
8. 1997 USPHS/IDSA report on the prevention of opportunistic infections in persons infected with human immunodeficiency virus
9. Preventing opportunistic infections in persons infected with HIV: 1997 guidelines
10. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for use of antiretroviral agents in HIV-infected adults and adolescents
11. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis
12. Purpose of quality standards for infectious diseases
13. The risk of Pneumocystis carinii pneumonia
14. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: Reassessment of indications for chemoprophylaxis
15. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus
16. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiiency virus infection
17. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection
18. Efficacy and toxicity of 2 doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus
19. A randomized trial of daily and thrice weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected individuals
20. Low-dose trimethoprim-sulfamethoxazole prohylaxis for toxoplasmic encephalitis in patients with AIDS
21. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group protocol 021
22. + persons at risk for PCP and with prior treatment-limiting rash or fever
23. ACTG 268 Trial: Gradual initiation of trimethoprim/sulfamethoxazole (T/S) as primary prophylaxis for Pneumocystis carinii pneumonia (PCP)
24. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV
25. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients
26. Atovaquone (ATQ) suspension for prophylaxis of Pneumocystis carinii pneumonia: Effects of baseline prophylaxis on safety and efficacy
27. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim; sulfonamides, or both
28. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy
29. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection
30. Discontinuation of Pneumocystis carinii pneumonia prophylaxis in HIV-1-infected patients treated with highly active antiretroviral therapy
31. + T-lymphocyte count
32. Discontinuation of PCP prophylaxis (PRO) is safe in HIV-infected patients (PTS) with immunological recovery with HAART preliminary results of an open, randomized and multicenter clinical trial (GESIDA 04/98)
33. 1995 Revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus
34. Treatment of toxoplasmic encephalitis in patients with AIDS: A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine
35. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS
36. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease
37. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency: Virus principles of therapy and revised recommendations
38. ACTG 196/CPCRA 009 Study Team. A phase III prospective, randomized, double-blind study of the safety and efficacy of clarithromycin (CLA) vs. rifabutin (RBT) vs. CLA + RBT for prevention of Mycobacterium avium complex (MAC) disease in HIV + patients with CD4 counts less than or equal to 100 cells/μL
39. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome
40. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both
41. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus
42. Reducing morbidity and mortality among patients with advanced human immunodeficiency virus infection
43. A placebo-controlled trial of rifabutin added to a regimen of clarithromycin and ethambutol in the treatment of M. avium complex (MAC) bacteremia
44. ACTG223: An open, prospective, randomized study comparing efficacy and safety of clarithromycin (C) plus ethambutol (E), rifabutin (R), or both for treatment (Rx) of MAC disease in patients with AIDS
45. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: A randomized, doubleblind, dose-ranging study in patients with AIDS
46. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high dose clarithromycin
47. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection
48. Chlamydia in pregnancy: A randomized trial of azithromycin and erythromycin
49. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients
50. Pneumococcal vaccination and the incidence of pneumonia among HIV-infected persons
51. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
52. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins for persons with altered immunocompetence
53. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection
54. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection: A randomized, double-blind, placebo-controlled trial
55. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS
56. Multiple malformation syndrome following fluconazole use in pregnancy: Report of an additional patient
57. Fluconazole-induced congenital anomalies in three infants
58. Janssen Pharmaceutical. Product information: Sporanox (itraconazol) oral solution
59. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: Randomized, placebo-controlled, double-blind study
60. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome
61. Fluconazole (FLU) vs. itraconazole (ITRA) for coccidioidomycosis: Randomized, multicenter, double-blinded trial in nonmeningeal progressive infections
62. Oral ganciclovir for the prevention of cytomegalovirns disease in persons with AIDS
63. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals
64. Phase III international study of valacyclovir (VACV) for cytomegalovirus (CMV) prophylaxis in patients with advanced HIV disease
65. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant
66. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS
67. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC peripheral cytomegalovirus retinitis trial
68. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS
69. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcomes in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir
70. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy
71. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients
72. + counts
73. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men
74. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: A double-blind, placebo-controlled trial
75. Centers for Disease Control and Prevention. Pregnancy outcomes following systemic prenatal acyclovir exposure: June 1, 1984-June 30, 1993
76. Interim guidelines for management of abnormal cervical cytology
77. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men
78. Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: A randomized trial
79. Centers for Disease Control and Prevention. Recommendations for prevention, and control hepatitis C virus (HCV) infection and HCV-related chronic disease
80. Incidence and risk factors for hepatitus C among injection drug users in Baltimore, Maryland
81. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
82. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
83. Hepatotoxicity after introduction of highly active antiretroviral therapy
84. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon in chronic hepatitis C
85. Hepatitis C
86. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis
87. Centers for Disease Control and Prevention. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
88. Centers for Disease Control and Prevention. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
89. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age
90. Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with HIV